Tocilizumab study for anti-MDA5 positive dermatomyositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old and weigh at least 45 kg.
- You must have a confirmed diagnosis of anti-MDA5 positive dermatomyositis with typical skin rashes.
- If you have lung involvement, your oxygen levels and lung function must meet specific minimums.
- You must have been on a stable, low dose of prednisone (a steroid) for at least 4 weeks before the study starts.
- You must also have been on a stable dose of a calcineurin inhibitor (like cyclosporine or tacrolimus) for at least 4 weeks, or have stopped other immune-suppressing drugs for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.